The Korean Pathfinder Lunar Orbiter (KPLO)-MAGnetometer (KMAG) consists of three triaxial fluxgate sensors (MAG1, MAG2, and MAG3) that measure the magnetic field around the Moon. The three sensors ...are mounted in the order MAG3, MAG2, and MAG1 inside a 1.2 m long boom, away from the satellite body. Before it arrived on the Moon, we compared the magnetic field measurements taken by DSCOVR and KPLO in solar wind to verify the measurement performance of the KMAG instrument. We found that there were artificial disturbances in the KMAG measurement data, such as step-like and spike-like disturbances, which were produced by the spacecraft body. To remove spacecraft-generated disturbances, we applied a multi-sensor method, employing the gradiometer technique and principal component analysis, using KMAG magnetic field data, and confirmed the successful elimination of spacecraft-generated disturbances. In the future, the proposed multi-sensor method is expected to clean the magnetic field data measured onboard the KPLO from the lunar orbit.
The Korea Pathfinder Lunar Orbiter (KPLO), the first South Korea lunar
exploration probe, successfully arrived at the Moon on December, 2022 (UTC),
following a 4.5-month ballistic lunar transfer ...(BLT) trajectory. Since the
launch (4 August, 2022), the KPLO magnetometer (KMAG) has carried out various
observations during the trans-lunar cruise phase and a 100 km altitude lunar
polar orbit. KMAG consists of three fluxgate magnetometers capable of measuring
magnetic fields within a ± 1,000 nT range with a resolution of 0.2 nT.
The sampling rate is 10 Hz. During the originally planned lifetime of one year,
KMAG has been operating successfully while performing observations of lunar
crustal magnetic fields, magnetic fields induced in the lunar interior, and
various solar wind events. The calibration and offset processes were performed
during the TLC phase. In addition, reliabilities of the KMAG lunar magnetic
field observations have been verified by comparing them with the surface vector
mapping (SVM) data. If the KPLO’s mission orbit during the extended
mission phase is close enough to the lunar surface, KMAG will contribute to
updating the lunar surface magnetic field map and will provide insights into the
lunar interior structure and lunar space environment.
The Korea Pathfinder Lunar Orbiter (KPLO), the first South Korea lunar exploration probe, successfully arrived at the Moon on December, 2022 (UTC), following a 4.5-month ballistic lunar transfer ...(BLT) trajectory. Since the launch (4 August, 2022), the KPLO magnetometer (KMAG) has carried out various observations during the trans-lunar cruise phase and a 100 km altitude lunar polar orbit. KMAG consists of three fluxgate magnetometers capable of measuring magnetic fields within a ± 1,000 nT range with a resolution of 0.2 nT. The sampling rate is 10 Hz. During the originally planned lifetime of one year, KMAG has been operating successfully while performing observations of lunar crustal magnetic fields, magnetic fields induced in the lunar interior, and various solar wind events. The calibration and offset processes were performed during the TLC phase. In addition, reliabilities of the KMAG lunar magnetic field observations have been verified by comparing them with the surface vector mapping (SVM) data. If the KPLO's mission orbit during the extended mission phase is close enough to the lunar surface, KMAG will contribute to updating the lunar surface magnetic field map and will provide insights into the lunar interior structure and lunar space environment.
Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid ...cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbacks. We investigated whether a nanocrystal (NC) formulation can address these issues and enhance anticancer efficacy of CFZ against breast cancer. The surface of NC was coated with albumin in order to enhance the formulation stability and drug delivery to tumors via interactions with albumin-binding proteins located in and near cancer cells. The novel albumin-coated NC formulation of CFZ (CFZ-alb NC) displayed improved metabolic stability and enhanced cellular interactions, uptake and cytotoxic effects in breast cancer cells in vitro. Consistently, CFZ-alb NC showed greater anticancer efficacy in a murine 4T1 orthotopic breast cancer model than the currently used cyclodextrin-based formulation. Overall, our results demonstrate the potential of CFZ-alb NC as a viable formulation for breast cancer therapy.
The discovery of NF-κB signaling pathways has greatly enhanced our understanding of inflammatory and immune responses. In the canonical NF-κB pathway, the proteasomal degradation of IκBα, an ...inhibitory protein of NF-κB, is widely accepted to be a key regulatory step. However, contradictory findings have been reported as to whether the immunoproteasome plays an obligatory role in the degradation of IκBα and activation of the canonical NF-κB pathway. Such results were obtained mainly using traditional gene deletion strategies. Here, we have revisited the involvement of the immunoproteasome in the canonical NF-κB pathway using small molecule inhibitors of the immunoproteasome, namely UK-101 and LKS01 targeting β1i and β5i, respectively. H23 and Panc-1 cancer cells were pretreated with UK-101, LKS01 or epoxomicin (a prototypic inhibitor targeting both the constitutive proteasome and immunoproteasome). We then examined whether these pretreatments lead to any defect in activating the canonical NF-κB pathway following TNFα exposure by monitoring the phosphorylation and degradation of IκBα, nuclear translocation of NF-κB proteins and DNA binding and transcriptional activity of NF-κB. Our results consistently indicated that there is no defect in activating the canonical NF-κB pathway following selective inhibition of the immunoproteasome catalytic subunits β1i, β5i or both using UK-101 and LKS01, in contrast to epoxomicin. In summary, our current results using chemical genetic approaches strongly support that the catalytic activity of the immunoproteasome subunits β1i and β5i is not required for canonical NF-κB activation in lung and pancreatic adenocarcinoma cell line models.
PDF
